0.1563
-0.0187 (-10.69%)
-0.0187 (-10.69%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 20,718,880 |
|
|||||
| News | (1) | ||||||
| Day High | 0.167 | Low High |
|||||
| Day Low | 0.1504 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| VistaGen Therapeutics Inc | VTGN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0187 | -10.69% | 0.1563 | 00:00:10 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.1657 | 0.1504 | 0.167 | 0.1574 | 0.175 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 15,837 | 20,718,880 | $ 0.1577809 | $ 3,269,044 | - | 0.1388 - 3.26 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:57:38 | formt | 7,000 | $ 0.1563 | USD |
Period:
Draw Mode:
VistaGen Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 32.30M | 206.64M | 206.42M | $ 1.11M | $ - | -0.25 | -0.70 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 155.00k | 0.30% |
VistaGen Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VTGN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.15 | 0.1875 | 0.1481 | 0.1655204 | 17,074,837 | 0.0063 | 4.2% |
| 1 Month | 0.9085 | 1.07 | 0.1388 | 0.1745855 | 26,000,024 | -0.7522 | -82.8% |
| 3 Months | 1.14 | 1.22 | 0.1388 | 0.2410318 | 9,935,944 | -0.9837 | -86.29% |
| 6 Months | 1.50 | 1.79 | 0.1388 | 0.3980668 | 5,362,263 | -1.34 | -89.58% |
| 1 Year | 2.74 | 3.26 | 0.1388 | 0.7398357 | 3,250,051 | -2.58 | -94.3% |
| 3 Years | 0.4959 | 3.55 | 0.10 | 1.24 | 2,170,147 | -0.3396 | -68.48% |
| 5 Years | 1.72 | 3.55 | 0.10 | 1.27 | 1,546,532 | -1.56 | -90.91% |
VistaGen Therapeutics Description
| VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression. |